Navigation Links
Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Date:10/5/2007

COLLEGEVILLE, Pa., Oct. 5 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), presented new data today from two Phase 3 studies, which showed that bazedoxifene/conjugated estrogens reduced the number and severity of hot flashes in symptomatic postmenopausal women by up to 80 percent, when compared with placebo. These data, presented at the North American Menopause Society Annual Meeting, also showed that bazedoxifene/conjugated estrogens improved symptoms of vulvar and vaginal atrophy. In addition, secondary data from both studies showed that when compared with placebo, bazedoxifene/conjugated estrogens reduced sleep disturbances and improved menopause-related quality of life.

"The pairing of bazedoxifene, a selective estrogen receptor modulator, or SERM, with conjugated estrogens may lead to a new class of menopausal therapy called tissue selective estrogen complex, or TSEC," says Ginger Constantine, M.D., Vice President, Women's Health Care and Bone Repair, Wyeth Pharmaceuticals. "TSECs pair the benefits of estrogens with SERMs to create a distinct clinical profile, which may provide relief of hot flashes and vaginal dryness as well as bone and uterine protection."

Update on NDA Filing

Wyeth plans to submit its New Drug Application (NDA) to the U.S. Food and Drug Administration for bazedoxifene/conjugated estrogens in the second quarter of 2008 subject to the further analysis and successful completion of product formulation, bioequivalence and clinical studies, and other remaining work necessary to finalize the NDA.

Significant Reduction of Hot Flashes and Relief of Vulvar and Vaginal Atrophy Symptoms

Results of a clinical trial titled "A Phase 3 Study of th
'/>"/>

SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008).... 1 Vical Incorporated (...$1.0 million milestone payment from Merck & Co...hase I clinical trial of an investigational plasmi... is based on Vical,s DNA gene delivery technology ... (hTERT). hTERT is the subject of separate license...
(Date:11/28/2008)...Nov. 28 Eli Lilly and Co...al New Drug Application (sNDA) from,the U.S. Food...loxetine HCl),for the management of chronic pain....irst half of 2009, adding data from a recently com...ain of the knee. , The decision does not af...
(Date:11/26/2008)... to 406 Subjects , , FRANKLIN, Mass., Nov. ... Bulletin Board: PLCSF) announced today that it ha...ug Administration (FDA) for its U.S. pivotal trial...Guard System(TM) and associated therapy in the pr... , The FDA also approved PLC,s request to ex...
(Date:11/25/2008)...CISCO, Calif., Nov. 25 Proteolix, ...f novel therapeutics that target,protein degradat...day,announced that data from two ongoing Phase 2 ...a will be presented at the upcoming 50th Annual Me.... Carfilzomib is the first in a new class,of spe...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Longs Drugs Partners With Google on the Launch of Google Health 19817 1Longs Drugs Partners With Google on the Launch of Google Health 19817 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 1bioMETRX Expands Engineering and Manufacturing Capabilities 3366 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 1TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 2TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 4Greener offices make happier employees 19812 1Greener offices make happier employees 19812 2
...itional Findings Reported on Glucose Homeostasis E...ne 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,... doses of the,investigational compound dapaglifloz...ansporter 2 (SGLT2) administered alone or,concomit...tes, no,discontinuations due to adverse events and...
...VILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/...hree Phase I trials,studying REP8839, a novel topi...vity against major skin pathogens including,methic...he Phase I,trials show that topically applied REP8...th low systemic exposure, or drug,absorption into ...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4
(Date:12/1/2008)...S, Dec. 2 While many Ame...ic challenges including rising costs of,basic nec...ess Scripts,(Nasdaq: ESRX ) has expanded Rx Out...escription medicines. , (Logo: http://www...OGO ) , Lower-income consumers can now rece...
(Date:12/1/2008)...O New research reveals that computed tomography (...y, has the potential to screen for two diseases at...hich commonly affect adults over age 50. Results o...meeting of the Radiological Society of North Ameri...to screening for colorectal cancer, we were able t...
(Date:12/1/2008)... Warren Presents Award, Engages with President on ...ome and Abroad During Saddleback Civil Forum on Gl...ire/ -- President George W. Bush was honored on th...he "International Medal of PEACE" given by Dr. Ric...uring the Saddleback Civil Forum on Global Health....
(Date:12/1/2008)...ls shut down and stop dividing when their DNA is d... so as to prevent damaged DNA from leading to unre...r, a new study, published in this week,s issue of ...ut down they also spew proteins into their surroun...s up conditions that support the development of ag...
Breaking Medicine News(10 mins):Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 2Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 3Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 4Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2
...d the glass jars over the slight incisions on his ... In the ensuing vacuum , the thick dark blood slow...ners. "The Assyrians, the Chinese and the ancient...ing to draw out the corrupt blood," said Hajam as ...
...arch groups described how they had quickly fallen ...ng pregnant making them feel stressed which they ...iving. They also reported becoming anxious that se...e. As the months passed and the couples did not f...
...sing weight to get into shape for her new movie 'K...a 'super-in-shape reporter' in her new movie , had...mits that she didn't like it one bit, and insists ... hardest things she's ever had to do, especially a...
... team of researchers has found evidence that peopl...mon sleep disorder called restless legs syndrome ...loping hypertension. RLS is a common and debilita...ffects the lives of tens of millions of people wor...
Other Medicine News:Health News:Ancient Healing Technique Gains New Popularity in Iraq 2Health News:Research Shows How Women Deal With the Stress When Trying for a Baby! 2Health News:Research Shows How Women Deal With the Stress When Trying for a Baby! 3Health News:Boffins Find Link Between Common Sleep Disorder and Hypertension 2
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: